Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 2/20 | 0.64 |
| ▸ | PGR | P06401 | 3/20 | 0.52 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.49 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.48 |
| ▸ | EDNRB | P24530 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21513796 | 1.00 | CCR4 (0.64) | CCR4PGRMAP3K20BRAFPIK3CG | |
| SCHEMBL22447546 | 0.86 | CCR4 (0.59) | CCR4MAP3K20PIK3CGPIK3CD | |
| SCHEMBL358926 | 0.86 | PIK3CG (0.63) | CCR4PIK3CGSLC40A1PTGES2PIK3CD | |
| SCHEMBL789565 | 0.83 | PIK3CA (0.57) | BRAFPIK3CGSLC40A1PIK3CD | |
| SCHEMBL29969152 | 0.83 | ALDH1A1 (0.50) | CCR4PIK3CGSLC40A1MAPT | |
| SCHEMBL21513797 | 0.83 | ALDH1A1 (0.50) | CCR4PIK3CGSLC40A1MAPT | |
| SCHEMBL22447721 | 0.82 | GLO1 (0.46) | CCR4MAP3K20PIK3CGPTGES2PIK3CD | |
| SCHEMBL22447736 | 0.81 | CCR4 (0.64) | CCR4EDNRBEDNRAWDR5 | |
| SCHEMBL789512 | 0.81 | KEAP1 (0.55) | EDNRBEDNRA | |
| SCHEMBL28549695 | 0.80 | PIK3CG (0.50) | CCR4PIK3CGPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | CCR4 4246/4885PGR 2294/4885MAP3K20 154/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | CCR4 4246/4885PGR 2294/4885MAP3K20 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.